Daniel Paterson is recorded as CEO at Verastem, Inc. (VSTM) since August 1, 2023 and Board Member at Verastem, Inc. (VSTM) since July 31, 2023. Verastem, Inc. reported in an 8-K filed August 4, 2023 that Daniel Paterson was appointed President and Chief Executive Officer, effective August 1, 2023. Verastem, Inc. reported in an 8-K filed July 12, 2023 that Daniel Paterson was appointed Class III director, effective July 31, 2023. Verastem, Inc. reported in an 8-K filed July 12, 2023 that Daniel Paterson was appointed President and Chief Executive Officer, effective July 31, 2023. The proxy statement of Verastem, Inc. reports total compensation of $1,736,172 for Daniel Paterson in fiscal 2019, including a base salary of $445,269. Daniel Paterson has spoken on 3 earnings calls and 2 other investor events across 1 company, most recently for Verastem, Inc. on June 23, 2026. Verastem, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Verastem, Inc. includes Brian M. Stuglik (CEO), Michael Bailey (CEO), Robert Forrester (CEO) and 7 others.
“As previously disclosed, Daniel Paterson was appointed to the position of President and Chief Executive Officer of Verastem, Inc. (the “Company”) effective as of August 1, 2023 (the “Effective Date”).”
Verastem, Inc. Form 8-K, filed August 4, 2023
· Read the filing
“In connection with his appointment, Mr. Paterson will also be appointed to the Board, to serve as a Class III director.”
Verastem, Inc. Form 8-K, filed July 12, 2023
· Read the filing
Daniel Paterson on recent calls
“We're excited to share the progress we've made across the VS 7375 development program and to discuss why we believe 7375 is a potential best-in-class, highly selective oral KRAS G12D on-off inhibitor that could become the preferred treatment option for patients with KRAS G12D mutated cancers.”
“Tomorrow marks one year since the accelerated approval of AvMAP defects in JACOPAC, a practice changing medicine approved for patients with KRAS-mutated recurrent low-grade serous ovarian cancer.”
“2025 was a truly transformative year for Veristem as we transitioned to a commercial stage company following our FDA approval of the first treatment specifically for KRAS-mutated recurrent low-grade serous ovarian cancer, nearly two months ahead of our PDUFA date.”
“Before we open the call to Q&A, I'll share a few final remarks to close out today's presentation. We've seen another strong quarter of execution at Veristam as we continue to deliver on all our strategic priorities, meeting our key milestones and delivering a strong commercial launch.”
